A Phase 2 interventional study of Tislelizumab in Colorectal Cancer, sponsored by BeiGene. Completed at 8 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-13.
Sponsored by BeiGene · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies testing tislelizumab in Colorectal Neoplasms — 15 open to participants now, 19 under way, 1 of them phase 3. tislelizumab · Colorectal Neoplasms.
Among the 27 studies testing tislelizumab in Colorectal Neoplasms, this one is the 12th largest by enrollment, is one of 4 that started in 2022, is one of 20 in phase 2, and was the 4th registered.
6,545 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →15 of the 27 studies testing tislelizumab in Colorectal Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Germany
Ages 18+
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · Sites in Austria, Germany
Ages 18+
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Sites in China
Ages 18–80
Sun Yat-sen University · Sites in China
Ages 18–80
Memorial Sloan Kettering Cancer Center · Sites in United States, Nigeria
Ages 18+
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 24 · Phase 3 1
First in 2021; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 76 across 4,805 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 33 across the 27 interventional studies. Of the 2 that completed or were terminated, 2 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 27 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 3 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing tislelizumab in Colorectal Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06520683Phase 3Sun Yat-sen UniversityAdjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer | 2027-11-01 |
| NCT06356597Jing-yuan Fang, MD, Ph. DTislelizumab With Fruquintinib, Metronidazole, in Mismatch Repair-proficient or Microsatellite Stability, Advanced Colorectal Cancer: a Multicenter, Single Arm, Clinical Trial | 2026-12-30 |
| NCT07025850Fudan UniversityEfficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer | 2027-01-01 |
| NCT07453875Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityLDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer | 2027-11-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 27 studies testing tislelizumab in Colorectal Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study was to help meet the medical needs of people in China with certain types of solid tumors that have specific genetic changes called microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR). The study looked at how well the drug tislelizumab works and how safe it is when given before surgery (neoadjuvant treatment) for these types of tumors.
This study enrolled participants with Stage II or III resectable colorectal cancer (CRC). Participants with unknown microsatellite instability (MSI) or mismatch repair (MMR) status provided blood and tumor tissue samples during a prescreening period (within 56 days before the first dose) for central laboratory confirmation of MSI status. Participants with known MSI-high (MSI-H) or deficient MMR (dMMR) status by local laboratory also underwent central confirmation when tumor samples were available. Eligible participants received tislelizumab 200 mg by intravenous infusion once every 3 weeks for 3 cycles as neoadjuvant therapy. After completion of neoadjuvant treatment, participants underwent complete surgical removal (R0 resection) of their tumor, and surgical specimens were assessed for pathological response, including major pathological response (MPR) and pathological complete response (pCR). Post-surgery, participants continued adjuvant therapy and follow-up as determined by their investigator.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Additional protocol-defined inclusion and exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tislelizumab 200 milligrams (mg) through an intravenous (IV) infusion once every 3 weeks for 3 treatment cycles before surgery (neoadjuvant therapy). After completing these 3 cycles, participants had their tumor surgically removed within 10 weeks of the first dose.
Drug: Tislelizumab
200 milligrams (mg) administered through an intravenous (IV) infusion once every 3 weeks for 3 treatment cycles
Also known as: BGB-A317, TEVIMBRA®
Major Pathological Response (MPR) Rate
MPR rate is defined as the percentage of participants whose resected primary tumor shows 10% or less remaining viable cancer cells after completing neoadjuvant therapy.
Time frame: Approximately 10 weeks after first dose of study treatment
Pathological Complete Response (pCR) Rate
Defined as the percentage of participants with a complete absence of residual tumor (no remaining cancer cells) in the surgically resected primary tumor and in all resected lymph nodes after completing neoadjuvant therapy.
Time frame: Approximately 10 weeks after first dose of study treatment
Event Free Survival (EFS)
Defined as the time from the first dose of study treatment until the first occurrence of any of the following events: * Disease progression that prevents complete surgical remover of the tumor * Local or distant recurrence after surgery * Death from any cause The median and other quartiles of EFS were estimated using the Kaplan-Meier Method.
Time frame: From first dose to final analysis data cutoff (03JAN2025), disease progression, initiation of a new anticancer therapy, or death; whichever came first. Median follow-up was 21.7 months.
2-Year and 3-Year Event Free Survival (EFS)
The 2-year and 3-year EFS rates are defined as the percentage of participants without any EFS events at 24 months and 36 months after the first dose. EFS rates were estimated by the Kaplan-Meier method with 95% CI estimated using Greenwood's formula.
Time frame: 24 months and 36 months after first dose
Number of Participants Experiencing Adverse Events
The incidence of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and immune-mediated adverse events (imAEs), was assessed for all participants who received at least one dose of study treatment. SAEs were defined as events that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability, or were considered important medical events. imAEs were defined as adverse events consistent with immune-related mechanisms, such as autoimmune-like toxicities requiring clinical evaluation or immunosuppressive management.
Time frame: From the first dose until 30 days (or 90 days for imAEs) after the last dose of tislelizumab, death, or start of new anticancer therapy, whichever occurred first (up to 03JAN2025). Maximum treatment duration was 2.3 months.
Participants were enrolled in multiple study centers in China.
| Milestone | Tislelizumab |
|---|---|
| Started | 33 |
| Received surgery | 29 |
| Completed | 0 |
| Not completed | 33 |
| Withdrew: Study completed by sponsor | 30 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Death | 1 |
MPR rate is defined as the percentage of participants whose resected primary tumor shows 10% or less remaining viable cancer cells after completing neoadjuvant therapy.
| Percentage of Participants | Tislelizumab |
|---|---|
| Major Pathological Response (MPR) Rate | 89.7 (72.6 to 97.8) |
Defined as the percentage of participants with a complete absence of residual tumor (no remaining cancer cells) in the surgically resected primary tumor and in all resected lymph nodes after completing neoadjuvant therapy.
| Percentage of Participants | Tislelizumab |
|---|---|
| Pathological Complete Response (pCR) Rate | 62.1 (42.3 to 79.3) |
Defined as the time from the first dose of study treatment until the first occurrence of any of the following events: * Disease progression that prevents complete surgical remover of the tumor * Local or distant recurrence after surgery * Death from any cause The median and other quartiles of EFS were estimated using the Kaplan-Meier Method.
| Months | Tislelizumab |
|---|---|
| Event Free Survival (EFS) | NA (NA to NA) |
The 2-year and 3-year EFS rates are defined as the percentage of participants without any EFS events at 24 months and 36 months after the first dose. EFS rates were estimated by the Kaplan-Meier method with 95% CI estimated using Greenwood's formula.
| Percentage of Participants | Tislelizumab |
|---|---|
| 24 Months (2-Year) | 93.9 (77.9 to 98.4) |
The incidence of treatment-emergent adverse events (TEAEs), including serious adverse events (SAEs) and immune-mediated adverse events (imAEs), was assessed for all participants who received at least one dose of study treatment. SAEs were defined as events that resulted in death, were life-threatening, required or prolonged hospitalization, caused significant disability, or were considered important medical events. imAEs were defined as adverse events consistent with immune-related mechanisms, such as autoimmune-like toxicities requiring clinical evaluation or immunosuppressive management.
| Participants | Tislelizumab |
|---|---|
| TEAEs | 33 |
| Serious AEs | 4 |
| imAEs | 10 |
Collected over All-cause mortality is reported from enrollment through to the end of the study, maximum duration was 35 months. Adverse events are reported from the first dose until 30 days (or 90 days for imAEs) after the last dose of tislelizumab, death, or start of new anticancer therapy, whichever occurred first; Maximum treatment duration was 2.3 months.. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab | 1/33 (3%) | 4/33 (12.1%) | 31/33 (93.9%) |
| Event | Tislelizumab |
|---|---|
| Cardiac arrestCardiac disorders | 1/33 |
| MyocarditisCardiac disorders | 1/33 |
| InflammationGeneral disorders | 1/33 |
| Skin infectionInfections and infestations | 1/33 |
| Event | Tislelizumab |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 18/33 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 11/33 |
| Wound complicationInjury, poisoning and procedural complications | 9/33 |
| Weight decreasedInvestigations | 6/33 |
| NauseaGastrointestinal disorders | 5/33 |
| FatigueGeneral disorders | 5/33 |
| C-reactive protein increasedInvestigations | 5/33 |
| HyperglycaemiaMetabolism and nutrition disorders | 5/33 |
| Sinus bradycardiaCardiac disorders | 4/33 |
| HyperthyroidismEndocrine disorders | 4/33 |
The Safety Analysis Set included all enrolled participants who received ≥ 1 dose of study drug
| Age, Continuous(years) | Tislelizumab |
|---|---|
| Mean | 51.9 ± 16.30 |
| Sex: Female, Male(Participants) | Tislelizumab |
|---|---|
| Female | 19 |
| Male | 14 |
| Race/Ethnicity, Customized(Participants) | Tislelizumab |
|---|---|
| Chinese | 33 |
| Region of Enrollment(participants) | Tislelizumab |
|---|---|
| China | 33 |
| The Eastern Cooperative Oncology Group (ECOG) Performance Status(Participants) | Tislelizumab |
|---|---|
| 0 (fully Active) | 27 |
| 1(Restrictive but Ambulatory) | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
Ran from Jan 2022 to primary completion in Sep 2023, 20 months.
Results were first posted in Feb 2026, 2 years 4 months after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's 20 months is below that.
Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab